Towards Curative Auto- Disable Syringes Dr Yvan Hutin Department of Blood Safety and Clinical Technology WHO, Geneva.

Slides:



Advertisements
Similar presentations
India Injection Safety Coalition. If you have an apple and I have an apple and we exchange these apples then you and I will still each have one apple.
Advertisements

Injection Safety Practices TOT Refresher Training of EPI Technicians Abbottabad -23 Feb 2012 Dr Bilal Ahmed Immunization Officer UNICEF.
Could the WHO Model List of Essential Medicines do more for the Rational and Safe Use of Injections? Logez S, Hutin Y, Holloway K, Robin G, Hogerzeil H.
Turning the tide: Not without prisons! Promoting comprehensive national HIV responses.
Beirut April 2011 Harm Reduction Coalition Policy Statement on Auto-Disable Syringes Dr Sharon Stancliff, Medical Director - New York Office.
Looked After Children SENCO meetings - November 2010 Education LAC Co-ordinator Education LAC Co-ordinator Sue Phillips Sue Phillips Danycoed HouseTel.
Community-Based Health Workers Can Safely and Effectively Administer Injectable Contraceptives: Conclusions from a Technical Consultation Consultation.
Managing Sharps Waste In Cambodia SIGN Meeting, 25 October 2002 Cambodiana Hotel, Phnom Penh Dr. Chea Kim Ly, Deputy Director National Immunization Program.
UNICEF Supply Division GMMM Geneva, Switzerland March 2011 Vaccine Supply Update – UNICEF’s role at global level.
Always practice proper hand hygiene and change gloves between each person. Label each individual piece of equipment with the resident’s name to prevent.
Medicines Transparency Alliance (MeTA) Presented to CSO workshops during 2013 in SOLWEZI AUGUST 27 NDOLA AUGUST 29 LUSAKA OCTOBER 22.
Injection Practices in Mongolia Results and Outcomes of the Rapid Assessment of Injection Practices Dr G. Soyolgerel Dr G. Soyolgerel Ministry of Health.
Harmonizing public health and public safety in a politically conservative environment Joëlle Rabot Field Coordinator Collectif Urgence.
Sol-Millennium MVP Injection Solution Contributor to Safety Injection In Immunization Service.
Equipment Used in Dosage Measurement
Best Infection Control Practices for ID, SC, and IM Injections Recommendations of the SIGN Working Group on Best Practices Geneva, October 2000 SIGN.
Global Measles and Rubella Management Meeting Progress and Challenges in Bangladesh March, 2011 Geneva, WHO HQ Dr Serguei Diorditsa.
1 Dr.I.A.Joshua 2 Dr JG Makama 3 Dr A Oyemecho 1 Department of Community/ 2 Department of Surgery Kaduna State University, Kaduna, Nigeria 3 Department.
APPMG BEAD meeting London, February 6, 2006 MALARIA VACCINES DEVELOPMENT: THE WAY AHEAD Joe Cohen, Ph.D. Vice President R&D Vaccines for Emerging Diseases.
© 2009 Delmar, Cengage Learning Chapter 8 Hypodermic Syringe Measurement.
Safe and Appropriate Use of Injection Activities of WHO’s Department of Blood Safety and Clinical Technology (BCT) Yvan Hutin Annual SIGN Meeting New Delhi.
Health System and Health System Strengthening in Nepal Dr BR Marasini, MBBS, MPH Senior Health Administrator Ministry of Health and Population.
11 Programme Strategies for Postpartum Family Planning: A new resource for FP programmes Mary Lyn Gaffield, PhD November 2013 Scientist, Human Reproduction.
Introduction of Auto-Disable (AD) Syringes Program for Appropriate Technology in Health Cairo, Egypt October 2000.
Safe Immunization Practices and Prevention of Hepatitis B and C Susan Mackay Behaviour Change Project Safe Injection Global Network.
INJECTABLES Nora A. Alkhudair. Injections Percutaneous introduction of a medicinal substance, fluid or nutrient into the body. (e. g. intradermal, subcutaneous,
Injection Safety IPV Global Workshop March 25, 2014.
“Getting to Zero” UNAIDS Strategy Dr. Paul De Lay, Deputy Executive Director, Programme UNAIDS.
Availability Accessibility Acceptability Quality Satisfaction Continuity of care Impacts Reach and outcomes Health Sector Non-Health Sector Outputs Education.
GAVI/Vaccine Fund Support to Improve Injection Safety On behalf of the Injection Safety sub-group.
Resource Needs Model Rachel Sanders October 28 th, 2010.
Introducing Curative AD (Auto-Disable) Syringes - Comments from AD Syringe Manufacturers SIGN Conference Cairo 2000.
Conclusions of the meeting and closing remarks. Chronology 1981Hepatitis B vaccine becomes available 1991World Health Assembly resolution call for the.
Towards ISO Standards for AD syringes: Update from WHO Gerald Verollet World Health Organization 3rd SIGN Meeting - New Delhi.
Increasing Access to Injection Equipment in Burkina Faso: When Essential Drugs Programmes Improve Injection Safety Sophie Logez Phamaciens Sans Frontières.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
1 1 Bose: SEAR Highlights and Priorities Global Measles & Rubella Management Meeting Geneva, March 2011 Accelerated Measles Control: Highlights and.
Measles Partnership Meeting Update on Vaccine Supply Washington, 27-28th February 2007 UNICEF Supply Division.
Public Perceptions about Injections and Private Sector Injection Practices in Central Nepal Mahesh Bhattarai and Scott Wittet.
Tuberculosis is a global public health issue. The Role of the International Agencies Introduction TB which stands for Tuberculosis is a rather infectious.
Update CASSI Select Committee 9 th March 2010 Adult Services Update CASSI Select Committee 9 th March 2010 Ann Workman Liz Hanley Simon Willson.
Working Draft - Last Modified :21:46 Printed UNITAID action plan - pediatric TB 0 “Securing timely access to quality, affordable TB drugs”
Meeting of the Working Group on TB Drug Development Why you need to be engaged? Marcos Espinal Executive Secretary Stop TB Partnership 29 October 2004.
October 31, 2014 Satellite Symposium: The pediatric TB drug market: progress and future direction Market understanding: new data on the purchasing habits.
A Pilot Intervention To Improve Injection Practices In The Informal Private Sector in Karachi, Pakistan Mubina Agboatwalla (1) Yvan Hutin (2) Steve Luby.
Estimating the Global Burden of HCV Infections Associated with Unsafe Health Care Injections Anja Hauri 1, Gregory Armstrong, 2 Yvan Hutin 1 1. WHO Headquarters,
1 Global Drug Facility presentation IPC meeting 10 December 2015 Magali Babaley Procurement, supply and country support manager.
3rd WHO Prequalification Stakeholders Meeting :Diagnostics 3rd Stakeholders Meeting on Prequalification Geneva, 4th February 2008 Update on Prequalification.
Documenting (Driving) Progress in Immunization Injection Safety Philippe Duclos, WHO Presented at the SIGN annual meeting, Cairo, Egypt, Oct th,
Copyright © 2015 Cengage Learning® Chapter 10 Reconstitution of Powdered Drugs.
Hypodermic Syringe Measurement
SPECIAL SESSION COUNTDOWN TO 2015 IN ETHIOPIA SIX BUILDING BLOCKS OF THE HEALTH SYSTEM: PROGRESS TOWARDS THE INTEGRATION IN ETHIOPIA Dereje Mamo Tsegaye.
Copyright © 2010 Delmar, Cengage Learning. ALL RIGHTS RESERVED. Chapter 8 Hypodermic Syringe Measurement.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
Abstract Problem Statement: As in many former socialist economies, anecdotal reports suggested that injections were overused to administer medications.
Report of the Finance and Audit Committee 1. For decision: Mid-term Review of the Voluntary Replenishment Product and Service Donations Budget 2009 For.
UNICEF Autodisable Syringe Supply Prepared for SIGN / TECHNET Delhi, 27-30Aug 2001.
Hepatitis C.
Parenteral Equipment and Supplies
Reconstitution of Powdered Drugs
Global Drug Facility An innovative approach to supplying anti-TB drugs
Logez S, Hutin Y, Somda P, Thualt J, Holloway K
CD-JEV administration in routine immunization
Ailsa Kennedy HETF Lead PENG
Health Technology Assessment for Universal Health Coverage
Reconstitution of Powdered Drugs
Issues on Dispensing Dr Percy Mahlathi.
5th DEWG meeting Conclusions
Difficult to prevent reuse of single use devices
Industrial Value Chain: A Bridge Towards a Carbon Neutral Europe
Presentation transcript:

Towards Curative Auto- Disable Syringes Dr Yvan Hutin Department of Blood Safety and Clinical Technology WHO, Geneva

Towards increased use of AD syringes in curative services Outline What are the needs? What is available? How do we set standards? How do we open the way? How do we move forward?

Towards increased use of AD syringes in curative services The need AD syringes: a success in immunization services –There is a demand –There is an offer –The experience in the field is positive Unmet needs in the curative services: –The number of injections is higher –Unsafe practices are highly prevalent –The informal private sector is difficult to reach –It is unclear whether sufficient quantities of single-use syringes would prevent reuse WHO milestone for the exclusive use of single-use injection equipment by 2005

Towards increased use of AD syringes in curative services Syringes available Mailed request to IASIT for available AD syringes of volumes exceeding 1 ml (March 2002). Two syringes on the market: –One syringe with retractable needle and active inactivation –One syringe with breakable plunger and passive inactivation Other manufacturers may have technologies up their sleeves

Towards increased use of AD syringes in curative services Setting standards Can the same concept be kept? –Larger volume Multiple injections of smaller volumes possible –Variable doses –Need of reconstitution How do we proceed? –Agreement from ISO to proceed on with a standard –Potential intermediate use of a WHO procurement specification

Towards increased use of AD syringes in curative services A programme to open the way The “stop TB” partnership –The Global TB Drug Facility (GDF) –Procurement of anti-TB drugs, including streptomycin Recent progress –Decision of Stop TB to “bundle” injectable medications –Disposable syringes first with transition to AD ASAP –Use of the GDF need to formulate a WHO procurement specification that can work as an interim “standard” –Tender expected towards the end of 2002

Towards increased use of AD syringes in curative services The way forward Support to GDF/ Stop TB to organize a first tender Set up of the ISO committee for ISO standard Promotion of the same “bundling” model for other donor or lender supported programmes Community intervention needed to support future policy statements regarding the use of AD syringes in health services